ARTICLE | Clinical News
PI-88: PGL began an Australian Phase II trial of PI-88 in patients with relapsed or refractory multiple myeloma. The product also is in U.S. Phase I/II testing
January 28, 2002 8:00 AM UTC
Progen Industries Ltd. (ASX:PGL; PGLAF), Brisbane, Australia Product: PI-88 Business: Cancer Therapeutic category: Angiogenesis Target: Blood vessels Description: Sulfated mannopentaose phosphate Ind...